Redx Immunology to start work this month

Redx Pharma’s new Alderley Park-based immunology division is set to start work this month. The launch of Redx Immunology, which focuses on developing new therapies for immune system disorders, was officially announced on 14 May 2015. The division is expected to create 50 jobs over two years, mostly in high-tech scientific positions.

Dr Neil Murray, chief executive of Redx Pharma, said: “The immunology group is a little bit different because we’re building on our existing capabilities. It’s a logical next step for us. We’re not starting from scratch here so hopefully we’ll see developments coming through in the next 12 months or so.”

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.